山东中农联合生物科技股份有限公司 独立董事 2024 年度述职报告 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人陈杰，出生于 1965 年 8 月，中国国籍，无境外永久居留权，博士学 历。1989 年 8 月至 1993 年 9 月，任辽宁省沈阳市农业局植保站农艺师；1993 年 9 月至 1994 年 8 月，任职于沈阳化工研究院；1994 年 9 月至 1997 年 7 月， 于南京农业大学攻读博士学位；1997 年 8 月至 2015 年 12 月，任浙江省化工研 究院生测安评中心主任；2016 年 1 月至今任浙江农林大学教师；目前兼任杭州 思海教育科技有限公司执行董事兼总经理、浙江世佳科技股份有限公司独立董 事、中国植物保护学会杂草学分会理事、农业部农药残留检测重点实验室学术 委员会委员、中国化工学会农药专业委员会委员、《农药学学报》常务编委。 因连续担任公司独立董事职务已满 6 年，本人于 2024 年 7 月起不再担任公司独 立董事职务。 本人符合相关法律法规、监管规章关于上市公司独立董事任职资格条件的 规定，已由深圳证券交易所备案审查。 （二）不存在影响独立性的情况 除担任公司独立 ...

山东中农联合生物科技股份有限公司董事会 关于独立董事独立性评估的专项意见 山东中农联合生物科技股份有限公司 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关规 定，山东中农联合生物科技股份有限公司（以下简称"公司"）董事会就公司现 任独立董事王贡勇先生、伍远超先生、杨光亮先生及离任独立董事陈杰女士的独 立性情况进行评估并出具如下专项意见： 董事会 经核查现任独立董事王贡勇先生、伍远超先生、杨光亮先生及离任独立董事 陈杰女士的任职经历以及签署的相关自查文件，上述人员未在公司担任除独立董 事以外的任何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股 东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系。鉴于此，公 司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律 监管指引第 1 号—主板上市公司规范运作》中对独立董事独立性的相关要求。 2025 年 4 月 26 日 ...

山东中农联合生物科技股份有限公司 独立董事 2024 年度述职报告 本人作为山东中农联合生物科技股份有限公司（以下简称"公司"）的独 立董事，2024 年严格按照《公司法》《上市公司独立董事管理办法》《深圳证 券交易所股票上市规则》等法律法规和《公司章程》《公司独立董事制度》等 相关规定，本着勤勉、忠实、诚信原则和对全体股东负责的态度，认真尽职地 监督公司运作，维护全体股东尤其是中小股东的合法权益。报告期内认真审议 各项议案，客观发表自己观点和意见，利用专业知识作出独立、公正的判断， 促进公司规范运作。现将 2024 年度的履职情况汇报如下： 一、个人履历和独立性说明 本人伍远超，出生于 1965 年 8 月，中共党员，法学硕士。1988 年 7 月参加 工作，历任司法部法律出版社编辑、中国出版集团中国民主法制出版社编辑、北 京博华律师事务所律师、北京君泰博华律师事务所律师、北京泰泽律师事务所律 师、北京直方律师事务所律师、中再资源环境股份有限公司独立董事。现任北京 腾铭律师事务所律师。2022 年 8 月至今任公司独立董事。 作为公司的独立董事，经自查，本人符合《上市公司独立董事管理办法》《深 圳证券交易所 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,013,624,015.34, representing a 19.79% increase compared to ¥1,680,905,154.51 in 2023[6]. - The net profit attributable to shareholders was a loss of ¥122,453,099.06, an improvement of 36.38% from a loss of ¥192,470,572.27 in the previous year[6]. - The cash flow from operating activities showed a net inflow of ¥104,897,433.18, up 20.71% from ¥86,903,287.02 in 2023[6]. - The total assets at the end of 2024 were ¥3,933,966,777.06, reflecting a 5.09% increase from ¥3,743,489,487.85 at the end of 2023[6]. - The company's basic and diluted earnings per share improved to -¥0.86, a 36.30% increase from -¥1.35 in 2023[6]. - The average return on equity was -8.67%, an improvement of 3.49% from -12.16% in the previous year[6]. - The pesticide sector contributed ¥1,958,250,592.99, accounting for 97.25% of total revenue, with a year-on-year growth of 23.48%[54]. - Revenue from pesticide formulations increased by 50.39% to ¥884,205,000.33, while raw pesticide revenue grew by 7.62% to ¥1,074,045,592.66[54][56]. - Domestic sales accounted for 62.90% of total revenue, increasing by 27.40% to ¥1,266,640,833.77, while international sales rose by 8.78% to ¥746,983,181.57[54]. Market Trends and Competition - The pesticide market is projected to grow at an annual rate of 5.1%, increasing from $58.2 billion in 2018 to $74.9 billion in 2023[25]. - The total sales revenue of the top 100 pesticide companies in China for 2024 was ¥261,346,000,000, a decrease of 20.22% year-on-year[27]. - The Chinese pesticide price index (CAPI) at the end of 2024 was 80.14, down 10.44% compared to the previous year[27]. - The global pesticide market sales reached $74.1 billion in 2022 and is expected to exceed $90 billion by 2030, with an annual growth rate of 2%-3%[30]. - Approximately 733 million people globally faced hunger in 2023, with 2.33 billion experiencing moderate to severe food insecurity, indicating a persistent need for agricultural inputs like pesticides[28]. - The Chinese government aims to stabilize grain production at over 1.3 trillion jin (approximately 650 million tons) as part of its food security strategy[29]. Research and Development - The company has obtained 68 domestic invention patents and 27 utility model patents, with 6 invention patents authorized in 40 countries[33]. - The company is involved in key national research projects, including the "Ecologically Friendly and Non-Polluting Major Insecticide Variety Creation and Industrialization" project[33]. - The company has developed a complete pesticide production and R&D system, focusing on safe, environmentally friendly, and efficient products[32]. - The company collaborates with prestigious universities such as Nankai University and Tianjin University to enhance its R&D capabilities[42]. - The company has a strong focus on R&D, with proprietary technologies that enhance product yield and reduce costs[37]. Production and Operations - The production capacity utilization for pesticide raw materials is at 64.26%, with a design capacity of 23,800 tons/year[38]. - The company is currently constructing an additional 1,300 tons/year capacity for pesticide raw materials[38]. - The company has achieved a significant reduction in wastewater generation, aligning with its clean production goals[38]. - The company has launched a 5,000t/a project for acetamiprid raw materials and a 10,000t/a project for dichloropentachloromethylpyridine, enhancing its production capacity[51]. - The company is focusing on optimizing production processes and reducing operational costs through various measures, including resource recycling and equipment upgrades[50]. Environmental Management - The company has implemented a comprehensive environmental management system, ensuring that wastewater and emissions meet relevant environmental standards through regular monitoring and treatment processes[167]. - The company has adopted a peak-shaving electricity strategy to reduce power consumption during peak hours, optimizing energy use and lowering costs[165]. - The company has fully transitioned to using natural gas as fuel, significantly reducing air pollution and environmental impact[165]. - The company has set a standard for nitrogen oxide emissions at 61.6496 tons, with a continuous monitoring system in place[157]. - The company has implemented a VOCs emission reduction project, significantly decreasing VOCs emissions through various treatment technologies, achieving compliance with emission standards[160]. Corporate Governance - The company has established a well-defined corporate governance structure, including a board of directors and supervisory board, ensuring independent operations[111]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[106]. - The company adheres to strict information disclosure practices, ensuring transparency and fairness for all shareholders[108]. - The company has established independent procurement, production, sales, and R&D systems, allowing for direct market operations[110]. - The company has implemented a comprehensive internal control system, ensuring effective separation of decision-making, execution, and supervision responsibilities[145]. Social Responsibility - The company donated agricultural products worth 50,000 yuan to impoverished residents in Cuijia Yu, Yishui County, to support local agricultural production[174]. - The company contributed over 60,000 yuan to rural schools in impoverished areas to improve educational conditions and enhance teaching quality[174]. - The company actively engages in social responsibility initiatives, focusing on poverty alleviation and rural revitalization efforts[186]. - The company has achieved a 100% training rate for all employees in safety training and a 100% certification rate for special operations personnel[179]. - The company has established a responsibility system for safety production, ensuring accountability at all levels of management[177]. Risk Management - The company recognizes potential risks from market competition and plans to maintain its competitive edge through continuous product innovation and optimization[96]. - The company acknowledges the risk of investment projects not meeting expected returns and will conduct thorough market assessments to minimize this risk[98]. - The company is focusing on risk avoidance during project implementation, emphasizing quality and progress in investment projects to achieve early production contributions[99]. - The company has been expanding into overseas markets, facing increased foreign exchange loss risks due to RMB exchange rate fluctuations, which could impact operational performance[99]. - The company plans to enhance its exchange rate trend analysis and utilize various financial derivatives to mitigate foreign exchange risks[99].

Financial Performance - The company's revenue for Q1 2025 was ¥519,949,745.15, representing an increase of 18.08% compared to ¥440,324,905.14 in the same period last year[5]. - The net profit attributable to shareholders was ¥4,058,964.92, a significant turnaround from a loss of ¥21,535,377.37 in the previous year, marking an increase of 118.85%[5]. - Basic and diluted earnings per share both improved to ¥0.03 from -¥0.15, reflecting a 120.00% increase[5]. - The total operating revenue for the current period reached ¥519,949,745.15, an increase of 18.0% compared to ¥440,324,905.14 in the previous period[18]. - The net profit for the period was ¥4,058,964.92, a significant recovery from a net loss of ¥21,535,377.37 in the previous period[20]. - The total comprehensive income for the period was ¥4,019,401.63, recovering from a loss of ¥21,582,466.77 in the previous period[20]. Cash Flow and Operating Activities - The net cash flow from operating activities was -¥58,379,604.81, showing an improvement of 9.01% compared to -¥64,159,479.74 in the same period last year[5]. - The operating cash flow net amount was -¥58,379,604.81, slightly improved from -¥64,159,479.74 in the prior period[22]. - The company received cash inflows from financing activities amounting to ¥111,302,705.56, compared to ¥252,924,345.00 in the prior period, reflecting a decrease of approximately 56.1%[22]. - The company reported a 141.50% increase in cash flow from financing activities, amounting to ¥1,953,917.11, compared to -¥4,708,442.71 in the previous year[9]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,928,229,131.09, a slight decrease of 0.15% from ¥3,933,966,777.06 at the end of the previous year[5]. - Total current assets amounted to ¥1,378,805,977.64, slightly down from ¥1,398,891,324.46, a decrease of 1.4%[14]. - Total liabilities decreased to ¥2,568,405,159.75 from ¥2,579,014,814.37, a reduction of 0.4%[16]. - The company's cash and cash equivalents decreased to ¥324,334,801.49 from ¥425,228,213.20, a decline of 23.7%[14]. - Cash and cash equivalents at the end of the period decreased to ¥109,334,801.49 from ¥209,827,159.88, a decline of approximately 47.9%[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,094[10]. - The largest shareholder, China Agricultural Production Materials Shanghai Co., Ltd., holds a 30.57% stake in the company[11]. Operational Metrics - Accounts receivable increased by 30.27% to ¥409,837,301.73, primarily due to increased revenue and outstanding receivables at the end of the reporting period[9]. - Accounts receivable increased to ¥409,837,301.73 from ¥314,608,088.67, reflecting a growth of 30.3%[15]. - Inventory decreased to ¥466,768,932.43 from ¥502,126,638.30, a decline of 7.0%[15]. - Research and development expenses decreased to ¥7,295,103.58 from ¥9,536,727.07, a reduction of approximately 23.4%[19]. - The total operating costs increased to ¥513,191,216.62 from ¥468,972,044.47, representing an increase of approximately 9.5% year-over-year[19]. Return on Equity - The company's weighted average return on equity increased to 0.30% from -1.47%[5].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：003042 证券简称：中农联合 公告编号：2025-002 山东中农联合生物科技股份有限公司关于举办 2024年度暨2025年第一季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 山东中农联合生物科技股份有限公司（以下简称"公司"）将于2025年4月26日在巨潮资讯网 （www.cninfo.com.cn）披露《2024年年度报告全文》《2024年年度报告摘要》及《2025年第一季度报 告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于2025年4月28 日（星期一）15:00-16:30在"价值在线"（www.ir-online.cn）举办2024年度暨2025年第一季度网上业绩说 明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。具体情况如下： 一、说明会召开的时间、地点和方式 （三）会议召开方式：网络互动方式 二、参加人员 董事长：许辉先生 董事、总经理：李凝先生 独立董事：王贡勇先生 副总经理、董事会秘书：颜世进先生 四、联系方式 ...

证券代码：003042 证券简称：中农联合 公告编号：2025-002 山东中农联合生物科技股份有限公司 关于举办 2024 年度暨 2025 年第一季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东中农联合生物科技股份有限公司（以下简称"公司"）将于 2025 年 4 月 26 日在巨潮资讯网（www.cninfo.com.cn）披露《2024 年年度报告全文》《2024 年年度 报告摘要》及《2025 年第一季度报告》。为便于广大投资者更加全面深入地了解公 司经营业绩、发展战略等情况，公司定于 2025 年 4 月 28 日（星期一）15:00-16:30 在"价值在线"（www.ir-online.cn）举办 2024 年度暨 2025 年第一季度网上业绩说明 会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。具体情况如下： 一、说明会召开的时间、地点和方式 （一）会议召开时间：2025 年 4 月 28 日（星期一）15:00-16:30 二、参加人员 董事长：许辉先生 董事、总经理：李凝先生 独立董事：王贡勇先生 副 ...

Financial Performance Forecast - The estimated net profit attributable to shareholders for 2024 is projected to be a loss of between 110 million and 136 million yuan, representing a 29.34% to 42.85% improvement compared to a loss of 192.47 million yuan in the previous year [2]. - The estimated net profit after deducting non-recurring gains and losses is expected to be a loss of between 115.2 million and 141.2 million yuan, showing a 28.96% to 42.04% improvement from a loss of 198.75 million yuan in the previous year [2]. - The basic earnings per share are projected to be a loss of between 0.77 yuan and 0.95 yuan, compared to a loss of 1.35 yuan per share in the previous year [2]. - There are no significant uncertainties affecting the accuracy of this earnings forecast [6]. - The financial data for 2024 will be finalized in the annual report, and the company will ensure timely information disclosure in compliance with legal regulations [6]. Market Strategy and Operations - The company is actively responding to market competition by increasing efforts in domestic and international market expansion and accelerating technological research and development [4]. - The company is focusing on optimizing product structure to enhance market competitiveness and has made progress in cost reduction and efficiency improvement [5]. - The company has seen a steady increase in product sales volume and operating income, leading to a reduction in the net loss attributable to shareholders compared to 2023 [5].

一、董事会召开情况 山东中农联合生物科技股份有限公司（以下简称"公司"）第四届董事会第 十二次会议于 2024 年 12 月 30 日在公司会议室以现场结合通讯方式召开。会议 通知已于 2024 年 12 月 26 日通过邮件及专人送达的方式通知到各位董事。本次 会议应出席董事 9 名，实际出席董事 9 名。本次会议由董事长许辉先生主持。会 议召开符合有关法律、法规和《公司章程》的规定，会议合法有效。 二、董事会会议审议情况 （一）审议通过《关于聘任公司副总经理的议案》 鉴于公司当前工作实际及未来发展需要，公司董事会决定聘任姜洪胜先生、 颜世进先生为公司副总经理，任期与公司第四届董事会任期一致。 证券代码：003042 证券简称：中农联合 公告编号：2024-050 山东中农联合生物科技股份有限公司 第四届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 三、备查文件 1、公司第四届董事会第十二次会议决议； 2、公司董事会提名委员会会议决议。 特此公告。 山东中农联合生物科技股份有限公司 董事会 2024 年 12 月 31 日 具体 ...

证券代码：003042 证券简称：中农联合 公告编号：2024-051 山东中农联合生物科技股份有限公司 关于高级管理人员变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东中农联合生物科技股份有限公司（以下简称"公司"）高级管理人员于 近日发生变动，现将有关事项公告如下： 一、公司高级管理人员辞职情况 公司董事会近日收到公司副总经理齐来成先生提交的书面辞职报告，齐来成 先生因工作调整原因，申请辞去公司副总经理职务，辞职报告自送达董事会之日 起生效。齐来成先生辞职后将担任公司纪委书记，并继续担任公司董事、董事会 战略委员会委员职务。 特此公告。 山东中农联合生物科技股份有限公司 董事会 2024 年 12 月 31 日 附件： 1、姜洪胜先生简历 姜洪胜先生，1976 年 6 月出生，中国国籍，无境外永久居留权，中共党 员，本科学历。历任山东联合销售员、市场部经理，中农作物总经理，公司市 场部经理、销售部副经理、销售部经理、办公室主任、总经理助理、副总经 理。现任公司纪委书记。 截至公告披露日，齐来成先生直接持有公司股份 2,600,000 股，并 ...